Scarica l'app Stockscreener
11.29
1.35%
-0.155
Dopo l'orario di chiusura:
11.29
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
Emerald Advisers LLC Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
(KROS) Investment Report - Stock Traders Daily
ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Keros Therapeutics (NASDAQ:KROS) Financial Analysis - Defense World
29,146 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Connor Clark & Lunn Investment Management Ltd. - Defense World
Bank of New York Mellon Corp Raises Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet - Yahoo Finance
AlphaQuest LLC Purchases 2,964 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
(KROS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine (NASDAQ:KROS) - Seeking Alpha
Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade - MSN
Equities Analysts Set Expectations for KROS Q1 Earnings - MarketBeat
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $42.33 - MarketBeat
FY2026 Earnings Estimate for KROS Issued By Leerink Partnrs - MarketBeat
HC Wainwright Issues Optimistic Outlook for KROS Earnings - MarketBeat
Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $42.33 - Defense World
Leerink Partnrs Has Bullish Outlook for KROS FY2026 Earnings - Defense World
Handelsbanken Fonder AB Boosts Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
HC Wainwright Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price - MarketBeat
Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $26.00 - MarketBeat
(KROS) On The My Stocks Page - Stock Traders Daily
Q1 EPS Forecast for Keros Therapeutics Lifted by Analyst - Defense World
What is William Blair’s Forecast for KROS Q1 Earnings? - Defense World
Keros Therapeutics (NASDAQ:KROS) Releases Earnings Results, Beats Expectations By $0.22 EPS - MarketBeat
Y Intercept Hong Kong Ltd Raises Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Q2 Earnings Estimate for KROS Issued By Leerink Partnrs - MarketBeat
Keros Therapeutics CEO to Speak at Major Conferences - TipRanks
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - The Manila Times
When and Where to Hear Keros Therapeutics' Latest Updates: CEO's March Conference Schedule - StockTitan
Keros Therapeutics Hold Rating: Uncertainty in KER-065 Development and Cibotercept Safety Concerns - TipRanks
Keros Therapeutics stock target cut to $40 at H.C. Wainwright By Investing.com - Investing.com South Africa
Analyst Expectations For Keros Therapeutics's Future - Benzinga
Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect - ACCESS Newswire
Keros Therapeutics Strengthens Financial Position Amid R&D Expansion - TipRanks
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - MSN
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Keros Therapeutics, Inc. SEC 10-K Report - TradingView
Keros Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Keros Therapeutics reports Q4 EPS ($1.14) vs. ($1.34) last year - TipRanks
How Keros Therapeutics Secured Funding Until 2029 Despite Widening Losses - StockTitan
0.98%
0.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):